Uzma Haque, MD, addressed the management of difficult-to-treat rheumatoid arthritis, using patient case reports to demonstrate clinical decision-making, during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.
Ana-Maria Orbai, MD, MHS, addressed the latest research into psoriatic arthritis (PsA), including a comprehensive overview of the latest FDA-approved treatments and their implications for clinical practice.
Meghan Berkenstock, MD, summarized key clinical pearls related to uveitis and rheumatic diseases during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.
As of July 1, a Florida bill increases oversight of pharmacy benefit managers and offers some protection for pharmacies. However, the legislation has limited effects on patients and providers, highlighting the need for additional reform.
Ongoing ACR advocacy efforts are working to keep biologic drugs accessible to rheumatology patients, defending the ability of rheumatology practices to use the complex chemotherapy codes for administration of biologic therapies.
A new award from the ACR’s RISE Registry and the Rheumatology Research Foundation supports early career rheumatology researchers and clinicians who leverage the registry’s real-world data in research projects.
We read the article, “Rheumatologists Share Lessons Learned in the Wake of Hurricane Ida” (July 2022, The Rheumatologist), with great interest. This poignant account of the impacted patients and rheumatologists provides invaluable planning tips regarding medication loss, access to pharmacies and medical records, and strategies to avoid practice losses. The critical lessons presented in this…
A prospective observational study by Syversen et al. found that patients with immune-mediated inflammatory diseases (IMID) had an attenuated serologic response to the standard two-dose vaccine regimen but a third dose was safe and effective.
The ACR RISE Registry staff highlights need-to-know information and key changes for the 2023 performance year as outlined in the proposed rule released July 7.
Glucocorticoids remain a prominent part of care for many patients with SLE but can have toxic side effects; this EULAR 2022 session discussed one institution’s approach to lower the dosage.